Christopher Brain
Overview
Explore the profile of Christopher Brain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
204
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fassl A, Brain C, Abu-Remaileh M, Stukan I, Butter D, Stepien P, et al.
Sci Adv
. 2020 Jul;
6(25):eabb2210.
PMID: 32704543
Inhibitors of cyclin-dependent kinases CDK4 and CDK6 have been approved for treatment of hormone receptor-positive breast cancers. In contrast, triple-negative breast cancers (TNBCs) are resistant to CDK4/6 inhibition. Here, we...
2.
Kim S, Tiedt R, Loo A, Horn T, Delach S, Kovats S, et al.
Oncotarget
. 2020 Apr;
11(14):1289.
PMID: 32292577
[This corrects the article DOI: 10.18632/oncotarget.26215.].
3.
Kim S, Tiedt R, Loo A, Horn T, Delach S, Kovats S, et al.
Oncotarget
. 2018 Nov;
9(81):35226-35240.
PMID: 30443290
Inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) is associated with robust antitumor activity. Ribociclib (LEE011) is an orally bioavailable CDK4/6 inhibitor that is approved for the treatment of hormone...
4.
Zhang Y, Sicinska E, Czaplinski J, Remillard S, Moss S, Wang Y, et al.
Mol Cancer Ther
. 2014 Jul;
13(9):2184-93.
PMID: 25028469
Well-differentiated/dedifferentiated liposarcomas (WD/DDLPS) are among the most common subtypes of soft tissue sarcomas. Conventional systemic chemotherapy has limited efficacy and novel therapeutic strategies are needed to achieve better outcomes for...
5.
Cho Y, Angove H, Brain C, Chen C, Cheng H, Cheng R, et al.
ACS Med Chem Lett
. 2014 Jun;
3(6):445-9.
PMID: 24900493
Herein, we describe the discovery of potent and highly selective inhibitors of both CDK4 and CDK6 via structure-guided optimization of a fragment-based screening hit. CDK6 X-ray crystallography and pharmacokinetic data...
6.
Mainolfi N, Powers J, Amin J, Long D, Lee W, McLaughlin M, et al.
J Med Chem
. 2013 Jun;
56(13):5464-72.
PMID: 23738526
Glaucoma is a leading cause of vision loss and blindness, with increased intraocular pressure (IOP) a prominent risk factor. IOP can be efficaciously reduced by administration of topical agents. However,...
7.
Cho Y, Borland M, Brain C, Chen C, Cheng H, Chopra R, et al.
J Med Chem
. 2010 Nov;
53(22):7938-57.
PMID: 21038853
Identification and structure-guided optimization of a series of 4-(pyrazol-4-yl)-pyrimidines as selective CDK4/6 inhibitors is reported herein. Several potency and selectivity determinants were established based on the X-ray crystallographic analysis of...
8.
Dyson A, Peacock M, Chen A, Courade J, Yaqoob M, Groarke A, et al.
Pain
. 2005 Jun;
116(1-2):129-37.
PMID: 15936883
CT-3 (ajulemic acid) is a synthetic analogue of a metabolite of Delta9-tetrahydrocannabinol that has reported analgesic efficacy in neuropathic pain states in man. Here we show that CT-3 binds to...